Asset Details
Do you wish to reserve the book?
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Do you wish to request the book?
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
2010
Overview
In this clinical trial, apixaban, an oral factor Xa inhibitor, was shown to be superior to enoxaparin for the prevention of thromboembolism after hip replacement, without an increase in the risk of bleeding.
Patients undergoing hip-replacement surgery require effective thromboprophylaxis, and low-molecular-weight heparins, vitamin K antagonists, and mechanical methods are now standard therapies. Despite prophylaxis, however, subclinical deep-vein thrombosis develops in approximately 15 to 20% of patients soon after surgery, and symptomatic venous thromboembolism develops in 2 to 4% during the first 3 months after surgery.
1
Practical limitations of current prophylactic techniques have stimulated a search for simpler methods. Low-molecular-weight heparins and fondaparinux require subcutaneous injection. Warfarin has a delayed onset of action and is relatively ineffective soon after surgery. Mechanical methods are cumbersome and relatively ineffective after hip surgery.
The development of . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Anticoagulants - adverse effects
/ Anticoagulants - therapeutic use
/ Arthroplasty, Replacement, Hip
/ Biological and medical sciences
/ Enoxaparin - adverse effects
/ Enoxaparin - therapeutic use
/ Female
/ Hemorrhage - chemically induced
/ Humans
/ Male
/ Postoperative Complications - prevention & control
/ Public health. Hygiene-occupational medicine
/ Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
